• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Boston Scientific earns Medicare reimbursement for Agent drug-coated balloon

August 1, 2025 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB
The Agent drug-coated balloon. [Image from Boston Scientific]

Boston Scientific (NYSE: BSX) announced today that CMS granted reimbursement for its Agent drug-coated balloon (DCB).

CMS granted a new technology add-on payment (NTAP) for eligible cases using Agent.

NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. Starting Oct. 1, 2025, CMS intends to provide hospitals with additional device reimbursement when the Agent DCB is used for eligible cases in the hospital inpatient setting.

Agent treats coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. It serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent ISR recurrence.

Boston Scientific won FDA approval for Agent last year, making it the first drug-coated coronary balloon available in the U.S. The company also offers it commercially in several international markets, with more than 100,000 patients treated with Agent globally.

“The CMS determination is a positive development for patients with in-stent restenosis and supports clinical findings that the Agent DCB is statistically superior to conventional balloon angioplasty for treating the condition,” said Lance Bates, SVP, Interventional Cardiology Therapies, Boston Scientific. “We applaud this ruling as it will allow hospitals to receive additional reimbursement when treating patients with the device, supporting access to the Agent DCB for Medicare beneficiaries.”

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations Tagged With: Boston Scientific, Centers for Medicare and Medicaid Services (CMS)

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS